Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Go back to Alnylam Reports Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy| Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) | Delayed: 260.10 -6.01 (2.26%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $266.11 | 52 Week High | $109.10 | |||
| Open | $259.00 | 52 Week Low | $31.38 | |||
| Day High | $272.08 | P/E | N/A | |||
| Day Low | $254.01 | EPS | $-1.45 | |||
| Volume | 2,008,635 | |||||
